Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20050067.LumA

— · A

446505c1-3e9a-5ae8-af03-2d823b3cda31

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • UV_RESPONSE_DN+0.390
  • TGF_BETA_SIGNALING+0.370
  • ESTROGEN_RESPONSE_EARLY+0.290
  • NOTCH_SIGNALING+0.260
  • PANCREAS_BETA_CELLS+0.240
  • MYOGENESIS+0.190
  • WNT_BETA_CATENIN_SIGNALING+0.190
  • COAGULATION+0.180
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.180
  • KRAS_SIGNALING_UP+0.150

Top 10 suppressed

  • E2F_TARGETS-0.640
  • G2M_CHECKPOINT-0.590
  • INTERFERON_ALPHA_RESPONSE-0.520
  • MTORC1_SIGNALING-0.470
  • MYC_TARGETS_V2-0.460
  • INTERFERON_GAMMA_RESPONSE-0.400
  • GLYCOLYSIS-0.390
  • MYC_TARGETS_V1-0.380
  • OXIDATIVE_PHOSPHORYLATION-0.360
  • MITOTIC_SPINDLE-0.350

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8613732
breast-umap@18
—A0.882
2TCGA-A2-A1G6-01A-11R-A13Q-07
breast-umap@18
—A0.874
3TCGA-EW-A1IX-01A-12R-A144-07
breast-umap@18
—A0.872
4C3N-02193
lung-landscapes@6
—cohortA10.865
5BSR_15_0097_A4_S88
breast-umap@18
—A0.860
6TCGA-HN-A2OB-01A-21R-A27Q-07
breast-umap@18
—A0.860
7TCGA-D8-A4Z1-01A-21R-A266-07
breast-umap@18
—A0.854
8SRR8613796
breast-umap@18
—A0.853
9s0122297
melanoma-umap@29
——0.851
10TCGA-A7-A5ZX-01A-12R-A29R-07
breast-umap@18
—A0.842

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
UV_RESPONSE_DN0.390Inavolisib— uncovered
TGF_BETA_SIGNALING0.370Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.290Inavolisib— uncovered
NOTCH_SIGNALING0.260Inavolisib— uncovered
PANCREAS_BETA_CELLS0.240Cobimetinib— uncovered
MYOGENESIS0.190Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered
COAGULATION0.180Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.180Inavolisib— uncovered
KRAS_SIGNALING_UP0.150Inavolisib— uncovered
ANDROGEN_RESPONSE0.110Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.110Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
APICAL_JUNCTION0.060Inavolisib— uncovered
P53_PATHWAY0.060Idelalisib— uncovered
APOPTOSIS0.040Idelalisib— uncovered
ANGIOGENESIS0.030Remibrutinib— uncovered
BILE_ACID_METABOLISM0.030Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.030Inavolisib— uncovered
IL2_STAT5_SIGNALING0.010Idelalisib— uncovered